Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q4 FY22 Earnings Presentation
15 slides from Zydus Lifesciences's earnings presentation, May 20, 2022
Slide 1: Zydus Lifesciences Limited Earnings Presentation
Zydus Lifesciences Limited Earnings Presentation 20th May, 2022 1
Slide 2: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 3: Q4 FY22: Financial Performance
Q4 FY22: Financial Performance Total Revenues* R&D Key Highlights of Q4 FY22 ❑ Ex-COVID related business, total revenues grew 7% yoy. Rs. 38,638 mn Rs. 2,697 mn ❑ India formulations business continued to display robust performance led 5% YoY 7% of revenues by strong momentum in branded portfolio. Ne
Slide 4: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) 38,638 152652 24,339 96,014 97,200 36,703 23,064 23,680 36,398 144035 Q4FY21 Q3FY22 Q4FY22 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 FY21 FY22 Total R&D (Rs. mn) and % to Revenues EBITDA ex. one-offs (Rs. mn) and Margin % 6.2% 7.0% 7.0%
Slide 5: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional, one-offs and discontinued ops.(Rs. mn) Capex (Rs. mn) 22988 5,069 5,250 20581 3,100 11,218 4,684 2,795 2,668 7,634 Q4FY21 Q3FY22 Q4FY22 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 FY21 FY22 Net debt/ EBITDA Net Working Capital* (Rs. mn) 48,765 49,188 46,289 1.03 4
Slide 6: India Formulations business
India Formulations business Branded business continued to display strong growth Highlights for the quarter India Formulations Sales Q4 FY22 Revenue India Formulations Sales ▪ Ex. COVID opportunities, Gx portfolio and divested (Rs. mn) Contribution (Rs. mn) products, the branded prescription business
Slide 7: Consumer Wellness
Consumer Wellness Focus on execution to accelerate the growth Highlights for the quarter Consumer Wellness Sales Q4 FY22 Revenue Consumer Wellness Sales (Rs. mn) Contribution (Rs. mn) ▪ Retained leadership position in 5 out of 6 brands in 5,984 6,330 their respective categories. 19,788 18,409 3,822
Slide 8: US Formulations business
US Formulations business Consolidating the position amidst challenging environment Highlights for the quarter US Formulations Sales Q4 FY22 Revenue US Formulations Sales ▪ Maintained top 3 ranking in ~ 60% of the product (Rs. mn) Contribution (Rs. mn) families in the US. 14,876 14,892 63,505 14,233
Slide 9: Emerging Markets Formulations business
Emerging Markets Formulations business Base business continued to display growth Highlights for the quarter EM Formulations Sales Q4 FY22 Revenue EM Formulations Sales (Rs. mn) Contribution (Rs. mn) ▪ Excluding COVID opportunities, the business grew by 2,914 11,921 29% on a YoY basis. 2,750 10,167 2
Slide 10: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Global pivotal Phase II(b)/III CT viz. EPICS-IIITM to evaluate the efficacy and safety of the molecule in patients with PBC is currently going on for the US market. • Patient enrolment ongoing for EVIDENCES-X, another global pivotal Phase II(b) CT
Slide 11: Updates on Innovation
Updates on Innovation NCE: ZYIL1 (NLRP3 inhibitor) • Initiated Phase II(a) CTs in Australia to study the safety, tolerability, pharmacokinetics and pharmacodynamics of the molecule in patients with CAPS in Australia. • The molecule is an oral NLRP3 inflammasome inhibitor targeted at selectively supr
Slide 12: Zydus at a Glance
Zydus at a Glance >$2 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 8 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Over Among 1st Revenues from branded Approved product for In 60% of product 50% business (India, EM and Top 3 families marketed in
Slide 13: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q4 Q4 YoY Q3 QoQ Rs. mn FY22 FY21 Gr. FY22 FY21 gr. FY22 gr. Total Income from Ops. 38,638 36,703 5.3% 36,398 6.2% 1,52,652 1,44,035 6.0% Comments for Q4 FY22: Gross Contribution (GC) 23,680 24,339 -2.7% 23,064 2.7% 97,200 96,014 1.2% • GC impacted by on
Slide 14: Details of Other Incomes and Exchange rate Fluctuations
Details of Other Incomes and Exchange rate Fluctuations Other Operating Income Q4 Q4 YoY YoY Rs. mn FY22 FY21 FY22 FY21 gr. gr. Export Incentive 98 98 -0.1% 470 1,164 -59.7% Exchange Rate Fluctuations 582 1,553 Processing Income 76 64 18.8% 309 237 30.4% Others 464 732 -36.7% 2,044 1,384 47.7% Total
Slide 15: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-71800839 For more information, please visit www.zyduslife.com Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway,